Bilateral Severe Panuveitis Occurring during Cancer Immunotherapy with Dabrafenib and Trametinib Therapy Due to Toxoplasmosis Reactivation

Safia Hsin; Theodor Stappler; Ann Schalenbourg; Yan Guex-Crosier

doi:10.1055/a-2004-5731

Klinische Monatsblätter für Augenheilkunde, Table of Contents

Klin Monbl Augenheilkd 2023; 240(04): 574-577
DOI: 10.1055/a-2004-5731

Der interessante Fall

Bilateral Severe Panuveitis Occurring during Cancer Immunotherapy with Dabrafenib and Trametinib Therapy Due to Toxoplasmosis Reactivation

Bilaterale schwere Panuveitis während einer Krebsimmuntherapie mit Dabrafenib und Trametinib aufgrund einer okulären Toxoplasmose-Reaktivierung

Safia Hsin

Ophtalmology, University of Lausanne, Jules-Gonin Eye Hospital, Lausanne, Switzerland

,

Theodor Stappler

Ophtalmology, University of Lausanne, Jules-Gonin Eye Hospital, Lausanne, Switzerland

,

Ann Schalenbourg

Ophtalmology, University of Lausanne, Jules-Gonin Eye Hospital, Lausanne, Switzerland

,

Yan Guex-Crosier

Ophtalmology, University of Lausanne, Jules-Gonin Eye Hospital, Lausanne, Switzerland

› Author Affiliations

Abstract

Full Text

References

References
1 Rali A, Huang Y, Yeh S. Cancer Immunotherapy and Uveitis: Balancing Anti-Tumor Immunity and Ocular Autoimmunity. Int Ophthalmol Clin 2022; 62: 49-63
2 Martins F, Sofiya L, Sykiotis GP. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019; 16: 563-580
3 Guex-Crosier Y, Auer C, Bernasconi O. et al. Toxoplasmic retinochoroiditis: resolution without treatment of the perilesional satellite dark dots seen by indocyanine green angiography. Graefes Arch Clin Exp Ophthalmol 1998; 236: 476-478
4 Dalvin LA, Shields CL, Orloff M. et al. CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects. Retina 2018; 38: 1063-1078
5 Thurau S, Engelke H, McCluskey P. et al. Uveitis in Tumor Patients Treated with Immunological Checkpoint- and Signal Transduction Pathway-Inhibitors. Ocul Immunol Inflamm 2021; 13: 1-7
6 Sun MM, Levinson RD, Filipowicz A. et al. Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition. Ocul Immunol Inflamm 2020; 28: 217-227
7 Morelli T, Fujita K, Redelman-Sidi G. et al. Infections due to dysregulated immunity: an emerging complication of cancer immunotherapy. Thorax 2022; 77: 304-311
8 Abdel Malek R, Wassef R, Rizk E. et al. Toxoplasmosis an Overlooked Disease: Seroprevalence in Cancer Patients. Asian Pac J Cancer Prev 2018; 19: 1987-1991
9 Wykes MN, Lewin SR. Immune checkpoint blockade in infectious diseases. Nat Rev Immunol 2018; 18: 91-104
10 Lu M, Zhang L, Li Y. et al. Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections. Thorac Cancer 2020; 11: 805-809
11 McBerry C, Dias A, Shryock N. et al. PD-1 modulates steady-state and infection-induced IL-10 production in vivo . Eur J Immunol 2014; 44: 469-479
12 Bhadra R, Gigley JP, Weiss LM. et al. Control of Toxoplasma reactivation by rescue of dysfunctional CD8+ T-cell response via PD-1-PDL-1 blockade. Proc Natl Acad Sci U S A 2011; 108: 9196-9201
13 Naranjo CA, Busto U, Sellers EM. et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245
14 Fekkar A, Bodaghi B, Touafek F. et al. Comparison of immunoblotting, calculation of the Goldmann-Witmer coefficient, and real-time PCR using aqueous humor samples for diagnosis of ocular toxoplasmosis. J Clin Microbiol 2008; 46: 1965-1967
15 Harper TW, Miller D, Schiffman JC. et al. Polymerase chain reaction analysis of aqueous and vitreous specimens in the diagnosis of posterior segment infectious uveitis. Am J Ophthalmol 2009; 147: 140-147.e2
16 Robert-Gangneux F, Sterkers Y, Yera H. et al. Molecular diagnosis of toxoplasmosis in immunocompromised patients: a 3-year multicenter retrospective study. J Clin Microbiol 2015; 53: 1677-1684
17 Labalette P, Delhaes L, Margaron F. et al. Ocular toxoplasmosis after the fifth decade. Am J Ophthalmol 2002; 133: 506-515
18 Farhadi A, Haniloo A, Fazaeli A. et al. PCR-based Diagnosis of Toxoplasma Parasite in Ocular Infections Having Clinical Indications of Toxoplasmosis. Iran J Parasitol 2017; 12: 56-62
19 Rajput R, Denniston AK, Murray PI. False Negative Toxoplasma Serology in an Immunocompromised Patient with PCR Positive Ocular Toxoplasmosis. Ocul Immunol Inflamm 2018; 26: 1200-1202
20 Mataftsi A, Fragkou A, Vezyri E. et al. Unusual toxoplasmic chorioretinitis in advanced age: a diagnostic problem. Semin Ophthalmol 2011; 26: 4-6
21 Fardeau C, Romand S, Rao NA. et al. Diagnosis of toxoplasmic retinochoroiditis with atypical clinical features. Am J Ophthalmol 2002; 134: 196-203
22 Mehta M, Rasheed RA, Duker J. et al. Vitreous evaluation: a diagnostic challenge. Ophthalmology 2015; 122: 531-537
23 Eschle-Meniconi ME, Guex-Crosier Y, Wolfensberger TJ. Endogenous ocular nocardiosis: an interventional case report with a review of the literature. Surv Ophthalmol 2011; 56: 383-415